{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CRS+-+Cytokine+Release+Syndrome",
    "query": {
      "condition": "CRS - Cytokine Release Syndrome"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 58,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CRS+-+Cytokine+Release+Syndrome&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T05:20:20.449Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04361552",
      "title": "Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebrovascular Accident",
        "Chronic Obstructive Pulmonary Disease",
        "Chronic Renal Failure",
        "Coronary Artery Disease",
        "Diabetes Mellitus",
        "Malignant Neoplasm",
        "SARS Coronavirus 2 Infection"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-04-07",
      "completion_date": "2020-06-02",
      "has_results": false,
      "last_update_posted_date": "2020-06-18",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04361552"
    },
    {
      "nct_id": "NCT04340232",
      "title": "Safety and Efficacy of Baricitinib for COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-03",
      "completion_date": "2021-10",
      "has_results": false,
      "last_update_posted_date": "2021-03-08",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04340232"
    },
    {
      "nct_id": "NCT06415656",
      "title": "VitalTraq for the Detection of CRS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hematologic Malignancy"
      ],
      "interventions": [
        {
          "name": "TempTraq",
          "type": "DEVICE"
        },
        {
          "name": "VitalTraq",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2024-10-13",
      "completion_date": "2025-07-07",
      "has_results": true,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06415656"
    },
    {
      "nct_id": "NCT03557749",
      "title": "Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immune and Microbial Reconstitution",
        "Systemic Viral Infection",
        "Acute-graft-versus-host Disease",
        "Chronic Graft-versus-host-disease",
        "Recurrent Malignancy",
        "Cytokine Release Syndrome",
        "Allogenic Related Donors",
        "Cell Therapy/Immunotherapy Patients"
      ],
      "interventions": [
        {
          "name": "Blood Sample",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Stool Sample",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Urine Sample",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Bronchoalveolar Lavage (BAL) fluid",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Gastrointestinal biopsy x 2-4",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Skin biopsy",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Skin, mouth, and/or ocular swab",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Apheresis Product",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Final cellular product",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 210,
      "start_date": "2018-09-21",
      "completion_date": "2023-08-15",
      "has_results": false,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03557749"
    },
    {
      "nct_id": "NCT02906371",
      "title": "Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoblastic Leukemia, Acute, Childhood"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "CART 19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "1 Year to 24 Years"
      },
      "enrollment_count": 80,
      "start_date": "2016-08",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02906371"
    },
    {
      "nct_id": "NCT04362813",
      "title": "Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 454,
      "start_date": "2020-04-30",
      "completion_date": "2020-12-22",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Glendale, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04362813"
    },
    {
      "nct_id": "NCT04351152",
      "title": "Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Disease 2019 (COVID-19) Pneumonia"
      ],
      "interventions": [
        {
          "name": "Lenzilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Humanigen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2020-05-05",
      "completion_date": "2021-03",
      "has_results": false,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04351152"
    },
    {
      "nct_id": "NCT04370236",
      "title": "INB03 for the Treatment of Pulmonary Complications From COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "INB03",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inmune Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2020-10-21",
      "completion_date": "2021-11-18",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 9,
      "location_summary": "Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Kosciusko",
          "state": "Mississippi"
        },
        {
          "city": "Southard",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04370236"
    },
    {
      "nct_id": "NCT05823571",
      "title": "Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Acute",
        "Myelodysplastic Syndromes",
        "Myelomonocytic Leukemia, Chronic",
        "T-cell Prolymphocytic Leukemia",
        "CML",
        "Myeloproliferative Disorders",
        "Multiple Myeloma",
        "Plasma Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "Itacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2023-07-06",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05823571"
    },
    {
      "nct_id": "NCT03755414",
      "title": "Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphocytic Leukemia",
        "Myelodysplastic Syndromes",
        "Non-Hodgkin Lymphoma",
        "Hodgkin Disease"
      ],
      "interventions": [
        {
          "name": "Stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)",
          "type": "OTHER"
        },
        {
          "name": "Human Activity Profile",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2019-09-04",
      "completion_date": "2024-05-26",
      "has_results": true,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-07-24T05:20:20.449Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03755414"
    }
  ]
}